Phase II

Saniona

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Saniona Reports Positive Topline Results from Phase 2 Trial of Tesomet in Hypothalamic Obesity

Lead Product(s): Tesofensine

Therapeutic Area: Nutrition and Weight Loss

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2020

Details:

Study results showed that Tesomet was safe and well tolerated. Robust efficacy data reported statistically significant improvements in body weight, waist circumference, and glycemic control.

Saniona

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Saniona completes its six months double blind Phase 2a trial of Tesomet in hypothalamic obesity

Lead Product(s): Tesofensine

Therapeutic Area: Nutrition and Weight Loss

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

A total of 18 patients, of the original 21 who started the trial, have now continued into the open-label extension part of the study.

Lipidio Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Lipidio Pharmaceuticals Launches with First Close of Series A Financing

Lead Product(s): GDD3898

Therapeutic Area: Nutrition and Weight Loss

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Maxim Merchant Capital

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Series A Financing March 03, 2020

Details:

The financing will support the development of its lead therapeutic candidate GDD3898.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Saniona

Saniona Reports Positive Topline Results from Phase 2 Trial of Tesomet in Hypothalamic Obesity

Saniona

Saniona completes its six months double blind Phase 2a trial of Tesomet in hypothalamic obesity

Lipidio Pharmaceuticals

Lipidio Pharmaceuticals Launches with First Close of Series A Financing